Trilogy Capital
BMY icon

Trilogy Capital’s Bristol-Myers Squibb BMY Stock Holding History

Trilogy Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$321K Sell
5,140
-795
-13% -$50.2K 0.01% 332
2026
Q2 		$342K Buy
5,935
+281
+5% +$16.1K 0.01% 315
2026
Q1 		$343K Sell
5,654
-262
-4% -$15.3K 0.02% 303
2025
Q4 		$319K Sell
5,916
-280
-5% -$13.5K 0.01% 303
2025
Q3 		$279K Buy
6,196
+1,558
+34% +$72.8K 0.01% 322
2025
Q2 		$215K Sell
4,638
-740
-14% -$36.3K 0.01% 355
2025
Q1 		$328K Sell
5,378
-18,732
-78% -$1.09M 0.02% 268
2024
Q4 		$1.36M Sell
24,110
-42,012
-64% -$2.35M 0.07% 164
2024
Q3 		$3.42M Buy
66,122
+419
+0.6% +$19.7K 0.17% 93
2024
Q2 		$2.73M Buy
65,703
+5,219
+9% +$234K 0.15% 112
2024
Q1 		$3.28M Buy
60,484
+7,678
+15% +$391K 0.19% 90
2023
Q4 		$2.71M Buy
52,806
+3,181
+6% +$167K 0.17% 102
2023
Q3 		$2.88M Buy
49,625
+42,287
+576% +$2.59M 0.2% 74
2023
Q2 		$475K Buy
7,338
+1,671
+29% +$112K 0.03% 175
2023
Q1 		$393K Buy
5,667
+1,108
+24% +$78.1K 0.03% 170
2022
Q4 		$328K Buy
4,559
+853
+23% +$64.3K 0.02% 189
2022
Q3 		$263K Sell
3,706
-6
-0.2% -$435 0.02% 157
2022
Q2 		$286K Buy
3,712
+221
+6% +$16.8K 0.02% 135
2022
Q1 		$255K Buy
+3,491
New +$234K 0.02% 155
2018
Q4 		– Sell
-523
Closed -$32K – 188
2018
Q3 		$32K Buy
523
+142
+37% +$8.43K ﹤0.01% 230
2018
Q2 		$21K Buy
381
+81
+27% +$4.38K ﹤0.01% 244
2018
Q1 		$19K Buy
+300
New +$19.3K ﹤0.01% 225

Other funds holding BMY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Trilogy Capital's BMY Position: Q3 2026 in Review

Trilogy Capital reduced its Bristol-Myers Squibb (BMY) stake by 13% in Q3 2026, selling an estimated $50.2K and leaving 5,140 shares worth $321K. The position accounts for 0.01% of the portfolio, ranked #332.

Trilogy Capital first reported a position in BMY in Q1 2018 and has held it in 22 quarters since. The position peaked at $3.42M in Q3 2024. 694 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Trilogy Capital held 5,140 shares of Bristol-Myers Squibb worth $321K as of Q3 2026.
  • Trilogy Capital sold 795 Bristol-Myers Squibb shares in Q3 2026, an estimated $50.2K.
  • Bristol-Myers Squibb made up 0.01% of Trilogy Capital's portfolio in Q3 2026, its #332 holding.
  • Trilogy Capital first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 22 quarters since.
  • Trilogy Capital's Bristol-Myers Squibb position peaked at $3.42M in Q3 2024.
  • 694 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Trilogy Capital's 13F filing for Q3 2026, filed 20 Oct 2026.